SKYE · Skye Bioscience, Inc.
$0.61
-0.01 (-1.45%)
At close · Jul 29
Going-concern doubt
— flagged May 11, 2026
Substantial doubt about the company's ability to continue as a going concern.
“These conditions give rise to substantial doubt as to the Company's ability to continue as a going concern within one year after the date that these financial statements are issued. After considering the plans to alleviate substantial doubt, management has concluded that there is substantial doubt about the Company's ability to continue as a going concern within one year after the date that these financial statements are issued.”View the 10-Q filed May 11, 2026
Market Cap
$21.61M
Shares
35.14M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$0.61
Open$0.61
Day$0.60–0.62
52W$0.57–4.99
Avg vol 30d124K
Short int1.1M · 3.0% float · 8.0d
Short vol30%
Last earningsMar 10, 2026
DataJan 2020–Jul 2026
Filing10-Q · May 11
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 11, 2026
AI Brief
TL;DR.
Bullish
Bearish
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceOverall
Strong Sell
SellHoldBuy
Technical
Sell
Momentum
Very Weak
Sentiment
Bearish
Fundamentals
Weak
Quant / Vol
Very High
Market backdrop
VIX 18.2 · elevated
Equity put/call 0.71
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−34%
below
Price vs 50-day avg
−15%
below
RSI (14)
39
neutral
MACD trend
Positive
52-week position
1%
near low
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−10%
trailing
6-month return
−34%
trailing
YTD return
−18%
this year
Relative strength
−41%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $1 › 200d $1 — 200d above 50d
Institutional flow
Distributing
5 of 40 funds reported for Jun 30 · net -24 sh shares · +1 new
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
3.00% of float · ▲ +10.9% MoM · 8.0 days cover
Volume signal
Reversal watch
High volume on a down day — possible exhaustion
Institution breadth
Steady
40 holders — mid 2-yr range
Squeeze score
59
elevated · 0–100
Fundamentals
EPS growth
−93%
Y/Y
Free cash flow
$-43.1M
Balance sheet
$5.9M
net cash
Quant / Vol
risk profile
Volatility
103%
annualized · 1-yr
Max drawdown
−88%
past year
ATR
7.7%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−34%
Bearish
Price vs 50-day avg
−15%
Bearish
RSI (14)
39
Neutral
MACD trend
Positive
Bullish
52-week position
1%
Bearish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross)
No cross
50d $1 › 200d $1 — 200d above 50d
Institutional flow
Distributing
5 of 40 funds reported for Jun 30 · net -24 sh shares · +1 new
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
3.00% of float · ▲ +10.9% MoM · 8.0 days cover
Volume signal
Reversal watch
High volume on a down day — possible exhaustion
Institution breadth
Steady
40 holders — mid 2-yr range
Price context
position in its 52-week range
52-wk low $1
Now $1 · 1%
52-wk high $5
vs 200-day avg -34%
vs 50-day avg -15%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
SKYE
this stock
Skye Bioscience, Inc.
|
$21.61M | -18.0% | — | — | 3.0% |
|
ONC
BeOne Medicines Ltd.
|
$474.96B | +8.8% | +22179.2% | 966.6 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$124.46B | +8.2% | +46.2% | 29.1 | 2.0% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$72.88B | -9.8% | +20.8% | 17.0 | 3.3% |
|
ARGX
Argenx SE
|
$54.57B | +3.7% | — | — | 2.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| SKYE | -6.0% | -9.6% | -33.9% | -11.3% | -18.0% |
| SPY | -1.0% | 0.0% | +7.4% | -0.8% | +8.6% |
| vs SPY | -5.0% | -9.6% | -41.3% | -10.5% | -26.7% |